BOSTON, Sept. 28, 2011 /PRNewswire/ -- SPENCER
PHARMACEUTICAL INC. (the "Corporation" or "Spencer") (OTC PINK:
SPPH). The Corporation is pleased to announce that it has entered
into an agreement with Notre-Dame Capital Inc. ("Notre-Dame") as its financial advisor.
"We are excited to engage Notre-Dame Capital Inc. and its
excellent team lead by Mr. Richard
Groome who has over 20 years experience in the financial
sector and is a former member of the Board of Directors of the CDNX
Exchange, the predecessor of the TSX Venture exchange," stated Dr.
Max Arella, CEO and President of
Spencer Pharmaceutical, "to implement a cohesive program that we
believe will increase the visibility of Spencer Pharmaceutical Inc.
within the investment community, in turn enhancing our likelihood
for future growth."
About Spencer Pharmaceutical
Spencer Pharmaceutical is a newly formed public company
specializing in the identification of new drug delivery
applications. A global player in the biopharmaceutical market,
Spencer has forged relationships with two highly respected
laboratories located in Universities throughout the world. Our
focus is on newly patented formulation of existing drugs from the
incubation to the developmental stages. Our partners are
experienced researchers providing the Company years of research,
now ready for the drug-development status.
For further information please contact:
Spencer Pharmaceutical Inc.
Dr. Max Arella
T: (617) 973-5017
F: (617) 973-6403
E-mail: arellam@spencerpharmaceutical.com
Website: www.spencerpharmaceutical.com
About Notre-Dame Capital Inc.
Notre-Dame Capital is a Canadian exempt market dealer
specializing in the small and middle markets. The firm provides
innovative financing solutions to small and mid-size North American
issuers that specialize in oil & gas, mining, bio-technology,
internet technologies, agriculture, organic, natural products and
clean technology. Notre-Dame Capital also serves institutional
money managers and strategic investors worldwide who desire to
invest into quality and high-growth North American
opportunities.
For further information contact:
Notre-Dame Capital Inc.
T: (514) 907-4989
F: (514) 807-3449
Website: www.notredamecapital.com
Important Information
About Forward-Looking Statements in this press release
may be "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
"anticipate," "believe," "estimate," "expect," "intend" and similar
expressions, as they relate to the company or its management,
identify forward-looking statements. These statements are based on
current expectations, estimates and projections about the company's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and probably will,
differ materially from what is expressed or forecasted in such
forward-looking statements due to numerous factors, including those
described above. In addition, such statements could be affected by
risks and uncertainties related to the exploration for and
development of mineralized material, product demand, market and
customer acceptance, competition, pricing and development
difficulties, as well as general industry and market conditions and
growth rates and general economic conditions. Any forward-looking
statements speak only as of the date on which they are made, and
the company does not undertake any obligation to update any
forward-looking statement to reflect events or circumstances after
the date of this release. Information on the Company's website does
not constitute a part of this release.
SOURCE Spencer Pharmaceutical Inc.
